3 Biotech Stocks Trading At Least 43% Below Fair Value
Oil prices have pushed back to five month highs as conflict risks threaten energy supplies and feed straight into higher costs across the economy. That kind of squeeze often pushes investors toward areas where outcomes depend more on scientific progress than fuel prices, which is where higher risk biotech shares can look tempting. This article walks through three lab focused stocks with cleaner balance sheets that may interest you.
The three stocks highlighted below are just a sample, with the full biotech screen surfacing 87 more companies that carry similarly interesting stories and trade offs that are not covered here. To really size up this space, head straight into the Biotech Stocks screener to identify, filter, and analyze the biotech ideas that best fit your own risk and return preferences.
Arrowhead Pharmaceuticals (ARWR)
Overview: Arrowhead Pharmaceuticals develops RNAi based medicines targeting cardiometabolic and genetic diseases, with late stage candidates Plozasiran and Zodasiran anchoring its biotech focused pipeline.
Operations: Arrowhead Pharmaceuticals currently generates about US$669 million in Nanotechnology related revenue, all reported from the United States market.
Market Cap: US$8.3b
Arrowhead Pharmaceuticals matters for this Biotech Stocks screen because its RNAi drug portfolio aims directly at hard to treat cardiometabolic conditions. Turning promising data into a sustainable commercial engine is where the real investor decision now sits.
"The step up from a roughly 20 person FCS focused field team to coverage of about 20,000 SHTG target HCPs means Arrowhead Pharmaceuticals is committing to a much heavier fixed commercial base. If prescription growth tracks at the cautious end of management commentary, then SG&A intensity could remain elevated and delay any move toward operating leverage."
What happens when that ambitious buildout collides with a single pressure point on future demand will likely decide how quickly margins improve.
That single demand swing can reshape the story, and the full narrative for Arrowhead Pharmaceuticals shows how Arrowhead Pharmaceuticals could still turn this heavier commercial footprint into accelerating value creation for shareholders.
Supernus Pharmaceuticals (SUPN)
Overview: Supernus Pharmaceuticals develops and sells prescription drugs for central nervous system conditions such as ADHD, epilepsy, Parkinson’s disease, depression and related disorders.
Operations: Supernus Pharmaceuticals currently generates about US$830 million in pharmaceutical revenue, all reported from the United States market.
Market Cap: US$2.4b
For the Biotech Stocks theme, Supernus Pharmaceuticals matters because its ADHD and Parkinson’s treatments already reach patients today while a broader CNS pipeline sits behind them.
"Expanding patient pool for core products Qelbree and GOCOVRI remains a live driver, with Qelbree prescriptions growing faster than the overall ADHD market and adult use now exceeding pediatric use."
The performance of any major CNS product relative to expectations could influence whether future earnings power aligns with the optimism associated with this story.
That earnings swing is exactly what the full narrative for Supernus Pharmaceuticals unpacks, explaining how Supernus Pharmaceuticals could turn prescription momentum into durable cash generation while also highlighting where expectations may be mispriced.
Johnson & Johnson (JNJ)
Overview: Johnson & Johnson develops prescription medicines and MedTech products worldwide, with its Innovative Medicine drug portfolio anchoring its biotech relevance.
Operations: Johnson & Johnson currently generates about US$64.3b from Innovative Medicine and US$35.0b from MedTech across the United States and international markets.
Market Cap: US$621.2b
Johnson & Johnson brings a very different profile to this biotech focused list, pairing a large scale drug pipeline with a sizeable MedTech arm that can help manage some of the risks that come with complex biologic development.
"Johnson & Johnson anticipates accelerated growth in their portfolio and pipeline, particularly in the Innovative Medicine sector, despite the headwind from STELARA's loss of exclusivity."
A key consideration is how one pressure point in that high margin portfolio may shape future pricing dynamics and earnings resilience.
That pressure point is only part of the picture, and the full narrative for Johnson & Johnson connects Johnson & Johnson's pipeline, MedTech arm, and payout profile into a single, accelerating story.
Seeking Alternatives Before The Crowd Moves
Fresh ideas do not wait. Breakout moves, fading momentum, and stocks quietly flying under the radar for now can get caught quickly. Scan what others miss and act now.
- Target reliable income by scouting companies in the 6 dividend fortresses while yields still look attractive and prices have not fully caught up.
- Chase early momentum by tracking fast adapting businesses in the 39 profitable AI stocks that aren't just burning cash before their earnings strength pulls in the wider market.
- Secure exposure to real assets by reviewing miners in the 35 elite gold producer stocks while sentiment is still mixed and entry points remain reasonable.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com